Last updated: February 19, 2026
This report details the scope, claims, and patent landscape surrounding Russian Federation patent RU2015128024, titled "Preparation of Somatostatin-Containing Pharmaceutical Compositions" (translated). The patent, filed on July 11, 2013, and granted on July 20, 2015, claims a specific method for preparing somatostatin-containing pharmaceutical compositions. This analysis focuses on the technical and legal aspects relevant to drug development and investment.
What is the Subject Matter of RU2015128024?
Patent RU2015128024 concerns a method for the preparation of somatostatin-containing pharmaceutical compositions. The invention aims to provide a stable and effective pharmaceutical form of somatostatin. Somatostatin is a naturally occurring hormone that inhibits the release of several other hormones, including growth hormone, insulin, and glucagon. Its therapeutic applications include the treatment of acromegaly, certain pituitary adenomas, and carcinoid syndrome.
The patent describes a specific process involving the preparation of a dry, solid somatostatin-containing powder. Key elements of the claimed method include:
- Starting Material: The use of somatostatin or its synthetic analogs as the active pharmaceutical ingredient.
- Stabilizing Agents: Inclusion of specific excipients designed to enhance the stability of somatostatin. These are stated to be selected from a group comprising at least one of polyethylene glycol, dextran, or a combination thereof, and at least one of albumin or gelatin.
- Lyophilization (Freeze-Drying): The process involves freeze-drying the somatostatin solution in the presence of the stabilizing agents. This technique is crucial for obtaining a stable solid form of sensitive biomolecules like somatostatin, preserving their biological activity.
- Final Form: The resulting composition is a dry, stable powder that can be reconstituted for administration.
The patent emphasizes achieving a composition with high stability, meaning reduced degradation of somatostatin during storage and preparation. This is critical for ensuring consistent therapeutic efficacy.
What are the Specific Claims of RU2015128024?
The claims of RU2015128024 define the legal boundaries of the patented invention. The patent includes multiple claims, with Claim 1 being the broadest and subsequent claims providing narrower specifications.
Claim 1: The primary claim describes the method for preparing a somatostatin-containing pharmaceutical composition. This method comprises the steps of:
- Preparing an aqueous solution of somatostatin.
- Adding to the solution at least one stabilizing agent selected from the group consisting of polyethylene glycol, dextran, or their mixtures.
- Adding to the solution at least one stabilizing agent selected from the group consisting of albumin, gelatin, or their mixtures.
- Subjecting the resulting solution to lyophilization.
The claim specifies that the ratio of somatostatin to the total amount of stabilizing agents is from 1:5 to 1:1000. This ratio is a critical parameter for achieving the desired stability.
Dependent Claims: The patent also includes dependent claims that further refine the scope of the invention by specifying particular embodiments or preferred parameters. These may include:
- Specific types or molecular weights of polyethylene glycol or dextran used.
- The concentration ranges of the stabilizing agents.
- Specific freeze-drying cycles (e.g., freezing temperature, drying temperature, duration).
- The use of specific synthetic analogs of somatostatin.
For instance, a dependent claim might specify the use of polyethylene glycol with a molecular weight between 4,000 and 20,000 Da, or albumin from a specific animal source. These narrower claims provide fallback positions and can be crucial for patentability and enforcement.
The exact wording of all claims, including dependent claims and their precise limitations, would need to be reviewed in the original Russian patent document. However, the core of the invention lies in the combination of specific stabilizers with somatostatin followed by lyophilization.
What is the Prior Art Landscape for Somatostatin Preparations?
The field of somatostatin formulations is well-established, with numerous patents and publications addressing the challenge of its inherent instability. Prior art generally falls into several categories:
- Peptide Stabilization Techniques: General methods for stabilizing peptides, including lyophilization, use of cryoprotectants and lyoprotectants (e.g., sugars, amino acids, polymers), and pH control.
- Specific Somatostatin Formulations: Patents describing specific salt forms, conjugates, or delivery systems designed to improve somatostatin's pharmacokinetic profile and stability. Examples include depot formulations for sustained release.
- Peptide Analogs: Development of more stable and potent somatostatin analogs (e.g., octreotide, lanreotide) which are themselves subject to patent protection.
- Manufacturing Processes: Patents detailing specific steps or equipment used in the production of peptide-based pharmaceuticals, including lyophilization processes.
The novelty of RU2015128024 lies in its specific combination of polyethylene glycol/dextran with albumin/gelatin as stabilizing agents for somatostatin during a lyophilization process, along with the defined ratio range. Prior art would need to be analyzed to determine if this precise combination and process were previously disclosed or obvious to a person skilled in the art.
A thorough prior art search would involve databases such as Espacenet, USPTO, WIPO, and specialized chemical and pharmaceutical literature. Key search terms would include "somatostatin," "stabilization," "lyophilization," "polyethylene glycol," "dextran," "albumin," and "gelatin."
What is the Potential for Patent Infringement?
Patent infringement occurs when a party makes, uses, sells, offers to sell, or imports a patented invention without authorization from the patent holder. For RU2015128024, infringement would likely arise from a competitor's manufacturing or commercialization of a somatostatin pharmaceutical composition that utilizes the claimed method of preparation.
Direct Infringement: This occurs when a product or process directly embodies all elements of at least one claim. A company preparing somatostatin using the specific combination of stabilizers (PEG/dextran and albumin/gelatin) and lyophilization as described in Claim 1 of RU2015128024 would be directly infringing.
Indirect Infringement: This includes:
- Inducement: Knowingly encouraging another party to directly infringe.
- Contributory Infringement: Selling a component specifically made for use in infringing the patent, knowing it will be used to infringe and that the component is not a staple article of commerce suitable for substantial non-infringing use.
Key Considerations for Infringement Analysis:
- Claim Construction (Markman Hearing Equivalent): The precise meaning and scope of terms within the patent claims are critical. This often involves interpreting terms based on their ordinary meaning, specification, and prosecution history.
- Product/Process Analysis: A detailed analysis of the competitor's product and its manufacturing process is required to determine if it meets all the limitations of a claim.
- Freedom to Operate (FTO) Analysis: Companies developing new somatostatin products must conduct FTO analyses to ensure their products do not infringe existing patents. This involves searching for relevant patents and assessing their claims against the company's intended product and processes.
Given the specificity of the claimed method, potential infringers would need to carefully design their manufacturing processes to avoid the patented steps and compositions. This might involve using different stabilizing agents, alternative stabilization methods, or avoiding lyophilization altogether, if commercially viable.
What is the Competitive Landscape and Market Relevance?
The market for somatostatin and its analogs is significant, driven by treatments for conditions like acromegaly, neuroendocrine tumors, and associated symptoms. Major pharmaceutical companies are active in this space.
Key Market Players and Products:
- Novartis: Sandoz division markets somatostatin formulations.
- Ipsen: Known for lanreotide (Somatuline®).
- Chiasma/Chiasma Pharma: Developed oral octreotide (Mycapssa®).
- Recordati: Markets octreotide and lanreotide products.
The competitive landscape is characterized by:
- Established Generics: Post-patent expiry of first-generation somatostatin analogs, generic versions have entered the market, increasing price competition.
- Biologics and Biosimilars: Somatostatin and its analogs are peptide-based biologics. The development of biosimilars is a significant factor in market dynamics.
- Innovation in Delivery Systems: Ongoing research focuses on improving patient convenience and adherence, such as long-acting injectables and oral formulations.
- New Therapeutic Indications: Expansion of somatostatin use into new or related disease areas.
Relevance of RU2015128024:
The patent RU2015128024, by protecting a specific preparation method, is relevant to companies manufacturing or developing somatostatin-containing pharmaceuticals. If this patent is held by a company that produces a commercially viable somatostatin product, it can:
- Block Competitors: Prevent generic manufacturers from using the patented preparation method for their somatostatin products.
- Provide a Competitive Edge: Offer a unique, stable formulation that may have advantages in shelf-life or ease of reconstitution compared to non-patented methods.
- Be a Target for Licensing: Companies seeking to use the patented method would need to negotiate a license with the patent holder, generating revenue for the patent owner.
The market value of this patent is directly linked to the commercial success of the somatostatin products manufactured using its claimed method. If the patent holder has a significant market share or intends to launch a new product based on this preparation, the patent's strategic importance increases.
What are the Regulatory Considerations for Somatostatin Pharmaceuticals?
The development and approval of somatostatin pharmaceuticals are subject to rigorous regulatory oversight by national health authorities, such as the Ministry of Health of the Russian Federation (Roszdravnadzor) for products marketed in Russia, and comparable agencies internationally (e.g., FDA in the U.S., EMA in Europe).
Key Regulatory Aspects:
- Active Pharmaceutical Ingredient (API) Quality: The somatostatin API must meet stringent quality standards. Its purity, potency, and impurity profile are critical.
- Manufacturing Process Validation: The entire manufacturing process, including the preparation method described in RU2015128024, must be validated to ensure consistency, reproducibility, and control of critical quality attributes. This includes validation of the lyophilization process and the addition of excipients.
- Stability Studies: Extensive stability studies are required to demonstrate that the drug product maintains its quality, potency, and purity throughout its intended shelf life under specified storage conditions. The stability achieved through the patented preparation method is a key selling point and a regulatory requirement.
- Analytical Methods: Validated analytical methods are needed to test the API and drug product for identity, strength, quality, and purity. This includes methods to quantify somatostatin and detect degradation products.
- Pharmacokinetics and Pharmacodynamics (PK/PD): Clinical studies are necessary to characterize how the drug is absorbed, distributed, metabolized, and excreted (PK) and what its effects are on the body (PD). The stability and consistent dosing facilitated by the preparation method directly impact PK/PD profiles.
- Clinical Efficacy and Safety: Rigorous clinical trials are required to demonstrate the drug's efficacy and safety for its intended therapeutic indication.
Impact of Patent on Regulatory Strategy:
A patented preparation method can influence regulatory strategy by:
- Differentiating Products: A unique, patented formulation can help a product stand out from generic competitors, even if the API is the same.
- Protecting Market Exclusivity: The patent provides market exclusivity, allowing the innovator to recoup R&D investment before generic competition arises.
- Facilitating Biosimilar Development: For biosimilars, demonstrating substantial similarity to the reference product is key. However, a competitor's patented manufacturing process, if critical to product attributes, could present hurdles for a biosimilar manufacturer wanting to replicate that specific process. They might need to develop an alternative, non-infringing process that yields a biosimilar.
Companies seeking to utilize the method described in RU2015128024 must ensure compliance with all relevant pharmaceutical manufacturing regulations in the target markets.
Key Takeaways
- Patent RU2015128024 protects a specific method for preparing stable somatostatin pharmaceutical compositions through lyophilization using a combination of polyethylene glycol/dextran and albumin/gelatin as stabilizers.
- The core of the invention lies in the precise formulation and process steps, including a defined ratio of somatostatin to stabilizers.
- The patent's claims define the scope of protection, preventing others from using the identical or substantially similar preparation method.
- The competitive landscape for somatostatin products is dynamic, with established players, generic competition, and ongoing innovation in delivery systems.
- Regulatory approval for somatostatin pharmaceuticals requires extensive validation of manufacturing processes, stability studies, and demonstration of efficacy and safety.
- The patent can provide a significant competitive advantage by blocking competitors' use of the specific preparation method and potentially offering a more stable, reliable product.
Frequently Asked Questions
-
What specific somatostatin analogs are covered by RU2015128024?
The patent explicitly mentions "somatostatin or its synthetic analogs." The exact scope of "synthetic analogs" would be interpreted based on the patent's claims and specification, but it generally refers to molecules with similar biological activity and structural homology.
-
Can a company use different ratios of stabilizers to avoid infringement?
Yes, modifying critical parameters like the ratio of somatostatin to stabilizers can be a strategy to avoid direct infringement if the new ratio falls outside the scope of the patent claims. However, claim interpretation and potential indirect infringement must be carefully assessed.
-
Does this patent cover the final therapeutic use of somatostatin?
No, RU2015128024 protects the method of preparation of the pharmaceutical composition, not its therapeutic use or the somatostatin molecule itself. Separate patents or regulatory exclusivities would cover these aspects.
-
What is the typical lifespan of a Russian Federation drug patent?
In Russia, standard patent term for inventions is 20 years from the filing date, subject to payment of annual renewal fees. For pharmaceutical products, an additional patent term extension (supplementary protection certificate) may be available, which can extend the term by up to five years, compensating for the time lost during the regulatory approval process.
-
How does the stability achieved by this method compare to other stabilization techniques for somatostatin?
The patent claims superior stability through the combination of specific excipients and lyophilization. Comparative data, typically presented in the patent's experimental section or subsequent scientific publications, would quantify this advantage against other known methods. Without such data, a definitive quantitative comparison cannot be made.
Citations
[1] Russian Federation Patent RU2015128024, "Preparation of Somatostatin-Containing Pharmaceutical Compositions" (translated). Filed July 11, 2013, Granted July 20, 2015.
